Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "MEA"

1694 News Found

Centre deploys high level team to Mumbai to take stock of Measles cases
News | November 10, 2022

Centre deploys high level team to Mumbai to take stock of Measles cases

The team will assist the State Health Authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures


SEBI approves IPO plans of PharmEasy and Wellness Forever Medicare
News | February 21, 2022

SEBI approves IPO plans of PharmEasy and Wellness Forever Medicare

The companies plan to use the proceeds to retire debt and expand operations


Vakrangee partners with PharmEasy to deliver medicines to remote areas
Digitisation | December 16, 2021

Vakrangee partners with PharmEasy to deliver medicines to remote areas

Vakrangee through its Nextgen Kendras and BharatEasy Mobile Superaap will now be able to provide medicines & healthcare services in remote areas of the country


Clarivate and BARDA collaborate to identify therapeutics that can be repurposed for medical countermeasures
Biotech | November 09, 2021

Clarivate and BARDA collaborate to identify therapeutics that can be repurposed for medical countermeasures

Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries


DSM increases price for polyamide 6 and 66 in EMEA
News | March 02, 2021

DSM increases price for polyamide 6 and 66 in EMEA

The price increases are due to the rising costs of raw materials.


Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results
Clinical Trials | March 24, 2026

Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results

The company plans to submit the vaccine for regulatory review


Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug
Clinical Trials | March 24, 2026

Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug

The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials


Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026
R&D | March 23, 2026

Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026

Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses